CSIMarket
 
Zynerba Pharmaceuticals Inc   (ZYNE)
Other Ticker:  
 
 


 
 ZYNE $1.3000 $0.0300 2.36%

 Volume (M): 838   Open : 1.26    52 Wk Avg :  0.65

 
 ZYNE $1.3000 $0.0300 2.36%

 Volume (M): 838   Open : 1.26    52 Wk Avg :  0.65




ZYNE Today's High: $1.34 ZYNE Shares One Week Perf: 7.44 %
ZYNE Today's Low: $ 1.26 ZYNE Shares 30 Day Performance: -2.26 %
Number of ZYNE Shares Traded (M): 838 ZYNE Share Price 52 Wk High: $ 1.40
Value of ZYNE's Shares Traded (M$): $ 1,089 ZYNE Share Price 52 Wk Avg: $0.65
Share Price at the Open: $1.26 ZYNE's Share Price 52 Wk Low: $0.25



  News about Zynerba Pharmaceuticals Inc's Stock Splits and Dividends

Zynerba Pharmaceuticals Calls on Investors to Seize Unique Opportunity in Partnership with Harmony Biosciences Tender Offer

Zynerba Pharmaceuticals Urges Stockholders to Tender Shares in Harmony Biosciences Tender Offer
DEVON, Pa., Oct. 04, 2023 - Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), a leading provider of innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, is urging all stockholders, including individual investors, to promptly tender their shares into the tender offer initiated by Harmony Biosciences Holdings, Inc. (Harmony) and its wholly owned subsidiary, Xylophone Acquisition Corp. (Purchaser). The offer aims to purchase all outstanding shares of Zynerba common stock, a move unanimously recommended by the Zynerba Board of Directors.
This significant development showcases the strong position Zynerba holds in the emerging market of cannabinoid therapies for neuropsychiatric disorders. With its transdermal delivery system, Zynerba has successfully established itself as a pioneer in this space, providing patients with safe and effective treatment options.

Zynerba Pharmaceuticals Encourages Stockholders to Evaluate Impending Tender Offer by Harmony Biosciences


Introduction
DEVON, Pa., Sept. 29, 2023 - Zynerba Pharmaceuticals Inc. (Nasdaq: ZYNE), a leading innovator in pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, has released a letter to its stockholders addressing the pending tender offer from Harmony Biosciences Holdings, Inc. In light of this development, it is crucial to analyze the impact of the news on Zynerba's shareholders and put it into context with their previous updates.
Share Price Performance and Context
As of the writing of this article, Zynerba Pharmaceuticals Inc.'s share price stands at $1.27. The year-to-date performance of the company has reached an impressive 131.29%. This signifies significant growth and market confidence in Zynerba's products and strategic direction.





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com